Causal Effects and Immune Cell Mediators of Prescription Analgesic Use and Risk of Liver Cancer and Precancerosis in European Population: A Mendelian Randomization Study
- PMID: 39062110
- PMCID: PMC11274554
- DOI: 10.3390/biomedicines12071537
Causal Effects and Immune Cell Mediators of Prescription Analgesic Use and Risk of Liver Cancer and Precancerosis in European Population: A Mendelian Randomization Study
Abstract
Diverse clinical observations and basic studies have been conducted to explore the implications of analgesic medications in liver diseases. However, the direct causal relationship between prescription analgesic use (PAU) and the risk of liver cancer and precancerosis remains unclear. Thus, we aimed to reveal the conceivable causal effect of PAU on liver cancer and precancerosis, with immune cells as mediating factors. Two-sample Mendelian randomization (MR) analyses were performed to ascertain the causality of PAU on liver cancer and precancerosis. Sensitivity analysis approaches were employed to assess the heterogeneity and pleiotropy of results. Our findings revealed a causal correlation between different PAUs and the risk of liver cancer and alcoholic liver disease (ALD). Specifically, salicylic acid derivatives (SADs) and anilide medications were found to have a protective effect on liver cancer. And non-steroidal anti-inflammatory drugs (NSAIDs) and anilide medications showed a causal impact on ALD. Finally, mediation analyses found that anilide medications influence liver cancer through different immune cell phenotypes. Our research provides new genetic evidence for the causal impact of PAU on liver cancer and precancerosis, with the mediating role of immune cells demonstrated, offering a valuable foundation for researching analgesic medications in liver cancer and precancerosis treatment.
Keywords: analgesics; immune cell; liver cancer and precancerosis; mendelian randomization.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
Causal effects and immune cell mediators between prescription analgesic use and risk of infectious diseases: a Mendelian randomization study.Front Immunol. 2023 Dec 21;14:1319127. doi: 10.3389/fimmu.2023.1319127. eCollection 2023. Front Immunol. 2023. PMID: 38193081 Free PMC article.
-
Causal relationship between anti-inflammatory drugs and cancer: a pan-cancer study with Mendelian randomization.Front Genet. 2024 May 24;15:1392745. doi: 10.3389/fgene.2024.1392745. eCollection 2024. Front Genet. 2024. PMID: 38854429 Free PMC article.
-
Causal effects of autoimmune diseases on temporomandibular disorders and the mediating pathways: a Mendelian randomization study.Front Immunol. 2024 Jul 9;15:1390516. doi: 10.3389/fimmu.2024.1390516. eCollection 2024. Front Immunol. 2024. PMID: 39044823 Free PMC article.
-
Plasma metabolites as mediators in immune cell-pancreatic cancer risk: insights from Mendelian randomization.Front Immunol. 2024 Jun 12;15:1402113. doi: 10.3389/fimmu.2024.1402113. eCollection 2024. Front Immunol. 2024. PMID: 38933268 Free PMC article.
-
Causal relationship between thyroid dysfunction and gastric cancer: a two-sample Mendelian randomization study.Front Endocrinol (Lausanne). 2024 Apr 26;15:1335149. doi: 10.3389/fendo.2024.1335149. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38737547 Free PMC article.
Cited by
-
Causal Effect of Immunocytes, Plasma Metabolites, and Hepatocellular Carcinoma: A Bidirectional Two-Sample Mendelian Randomization Study and Mediation Analysis in East Asian Populations.Genes (Basel). 2024 Sep 9;15(9):1183. doi: 10.3390/genes15091183. Genes (Basel). 2024. PMID: 39336774 Free PMC article.
References
-
- Llovet J.M., Willoughby C.E., Singal A.G., Greten T.F., Heikenwälder M., El-Serag H.B., Finn R.S., Friedman S.L. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: Pathogenesis and treatment. Nat. Rev. Gastroenterol. Hepatol. 2023;20:487–503. doi: 10.1038/s41575-023-00754-7. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources